
Scott Rodig
Vice Chair, Hematopathology · Beth Israel Deaconess Medical Center
Credentials: · · · · ·
History
- Present
Hematopathology · Beth Israel Deaconess Medical Center
- 2002–2005
Internal Medicine

Research
PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma
New England Journal of Medicine · 2015 · 2,937 citations
An immunogenic personal neoantigen vaccine for patients with melanoma
Nature · 2017 · 2,312 citations
Comprehensive analyses of tumor immunity: implications for cancer immunotherapy
Genome biology · 2016 · 1,837 citations

62 papers

50 papers

34 papers
- MA
30 papers
- JK
27 papers

26 papers

26 papers

22 papers · 20 as a resident
Grants
- 2025–2029
Dissecting CCL5 Contribution to Antigen Specific T Cell Responses in Head and Neck Cancers
National Institute of Dental and Craniofacial Research · R01
PI · $3.7M · Dana-Farber Cancer Inst
- 2013–2029
Targetable Epigenetic and Transcriptional Mechanisms in Melanoma Thatshape the Microenvironment
National Cancer Institute · P01
Project lead · $520.7K · Massachusetts General Hospital
- 2020–2023
National Cancer Institute · R33
PI · $1.4M · Broad Institute, Inc.

